Every paper.
Searchable archive.

2026·Blood·2026 Jan 27 (online)·Middle author

The C/EBPα-(PU.1-LOUP) regulatory circuit regulates monocyte/macrophage development and immune functions

2025·Haematologica·110(11):2702-2713·Middle author

A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of JAK2V617F-induced polycythemia vera

2023·Blood Cancer Journal·13(1):171·Corresponding (last)

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm

2022·Nature Communications·13(1):5347·Corresponding (last)

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm

Drives the IL-1 inflammation theme · UVA press

2022·Leukemia·36(3):746-759·Corresponding (last)

Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models

Drives NCT04176198 (TP-3654 / Nuvisertib) · UVA Cancer Center is a major site

2021·Cancer Research·81(16):4332-4345·Corresponding (last)

CDK6 Is a Therapeutic Target in Myelofibrosis

2021·Leukemia·35(8):2382-2398·Corresponding (last)

U2af1 is required for survival and function of hematopoietic stem/progenitor cells

Anchor MDS / splicing paper · basis for active R01 NHLBI

2019·JACC: Basic to Translational Science·4(6):684-697·Middle author

JAK2 (V617F)-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure

2018·British Journal of Haematology·180(6):911-915·Corresponding (last)

STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice

2017·Blood·130(7):920-932·Corresponding (last)

Hmga2 promotes the development of myelofibrosis in Jak2(V617F) knockin mice by enhancing TGF-β1 and Cxcl12 pathways

2017·Leukemia·31(5):1229-1234·Corresponding (last)

Deletion of Ptpn1 induces myeloproliferative neoplasm

2016·Blood·127(26):3410-3423·Corresponding (last)

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm

2016·Blood·127(14):1803-1813·Middle author

Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1

2015·Leukemia·29(10):2050-2061·Corresponding (last)

Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice

2014·Stem Cells·32(7):1878-1889·Corresponding (last)

Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells

2014·Leukemia·28(8):1627-1635·Corresponding (last)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice

2012·Blood·120(9):1888-1898·Corresponding (last)

Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice

2012·Blood·119(16):3779-3789·Corresponding (last)

Efficacy of vorinostat in a murine model of polycythemia vera

2012·Haematologica·97(9):1389-1393·Corresponding (last)

Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice

2012·Blood·119(15):3539-3549·Corresponding (last)

Critical requirement for Stat5 in a mouse model of polycythemia vera

Highly cited · STAT5 as critical JAK2V617F effector

2011·FEBS Letters·585(7):1007-1013·Corresponding (last)

Differential biological activity of disease-associated JAK2 mutants

2010·Blood·115(17):3589-3597·Corresponding (last)

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

Foundational JAK2V617F knock-in model · the lab's signature mouse

2009·Blood·113(18):4414-4424·Middle author

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

2007·Cancer Biology & Therapy·6(2):195-201·Middle author

Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer

2007·Current Opinion in Genetics & Development·17(1):23-30·First author

The role of Shp2 (PTPN11) in cancer

Highly cited review

2005·Molecular and Cellular Biology·25(18):8001-8008·Middle author

Phosphatidylinositol 3-kinase p85α subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences

2005·Cancer Cell·7(2):179-191·First author

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations

Landmark first-author Cancer Cell · Shp2 as oncogenic phosphatase

2004·Nature Medicine·10(8):849-857·Middle author

Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation

2004·Proceedings of the National Academy of Sciences USA·101(9):3130-3135·First author

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

First-author PNAS · combination therapy template

2002·Cancer Cell·1(5):479-492·Co-first author

Critical role for Gab2 in transformation by BCR/ABL

Co-first author · most-cited paper

2000·Oncogene·19(4):571-579·Middle author

Analysis of mechanisms involved in the prevention of gamma irradiation-induced apoptosis by hGM-CSF

1998·Molecular Biology of the Cell·9(12):3299-3308·First author

Activation and functional analysis of Janus kinase 2 in BA/F3 cells using the coumermycin/gyrase B system

Tokyo PhD · first JAK2 paper